Expertise in
5
conditions

Karin T. Mayer

Sigmund Freud Str. 25, 
Bonn, NW, DE 
Expertise in
5
conditions
Sigmund Freud Str. 25, 
Bonn, NW, DE 

Overview

Karin Mayer practices practicing medicine in Bonn, Germany.

Ms. Mayer is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Febrile Neutropenia, Thrombectomy, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

Sigmund Freud Str. 25, Bonn, NW 53127, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)
Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug, Procedure
Study Drug: Ruxolitinib continuous therapy
Study Phase: Phase 2
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Cytarabine, Daunorubicin, Idarubicin
Study Phase: Phase 3
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Enrollment Status: Completed
Publish Date: February 27, 2023
Intervention Type: Drug
Study Drug: Gemtuzumab
Study Phase: Phase 3
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
Enrollment Status: Terminated
Publish Date: December 02, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

64 Total Publications

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.
Journal: Haematologica
Published: October 17, 2025

Frequently Asked Questions about Karin T. Mayer

Is Karin T. Mayer a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Karin T. Mayer is classified as an Advanced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Karin T. Mayer participate in research or clinical trials?

Yes. Karin T. Mayer has published 64 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Karin T. Mayer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Mayer's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile